Clinical update on a new progestogen-gestodene.

Recent developments in hormonal contraception have occurred as a result of the development of new progestogens in the gonane series. These progestogens have facilitated gradual reduction in the dosage of both estrogen and progestogen in the combined oral contraceptives. Newer gonanes have greater contraceptive specificity and this presentation concerns one of these progestogens-gestodene. Studies evaluating gestodene with its predecessor levonorgestrel in women undergoing hysterectomy on pituitary ovarian function and genital tract changes have confirmed earlier laboratory data that it is a highly effective and specific inhibitor of pituitary ovarian function and a suppressor of genital tract reproductive function. Histological changes in the endometrium indicate a suppressive action anticipating good cycle control. Clinical studies in the United Kingdom and Europe with a combined product containing 30 ug ethinyl estradiol and 75 ug gestodene indicate good acceptance reliable ovulation inhibition and satisfactory cycle control. This progestogen with specific suppressive effect on the mechanisms controlling ovulation and ancillary contraceptive action in the genital tract has minimal influence on the systemic metabolic function at the dose prescribed. It therefore paves the way for further modification of formulations to enhance the range of available products for the various types of women requiring hormonal contraception. (Authors)